- Home
- XNCR vs DSGN Comparison
XNCR vs DSGN Comparison
Compare XNCR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | DSGN |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 819.6M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XNCR | DSGN |
|---|---|---|
| Price | $11.93 | $10.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $22.33 | $15.25 |
| AVG Volume (30 Days) | 648.0K | ★ 1.1M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $3.33 |
| 52 Week High | $18.69 | $17.25 |
Technical Indicators
Market Signals| Indicator | XNCR | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 37.04 |
| Support Level | $10.83 | $9.36 |
| Resistance Level | $12.87 | $10.59 |
| Average True Range (ATR) | 0.58 | 1.28 |
| MACD | 0.02 | -0.38 |
| Stochastic Oscillator | 46.07 | 6.76 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.